# Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early

> **NCT04398004** · PHASE2 · COMPLETED · sponsor: **Hellenic Institute for the Study of Sepsis** · enrollment: 90 (actual)

## Conditions studied

- COVID-19
- Virus Diseases
- Corona Virus Infection

## Interventions

- **DRUG:** Clarithromycin

## Key facts

- **NCT ID:** NCT04398004
- **Lead sponsor:** Hellenic Institute for the Study of Sepsis
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-06
- **Primary completion:** 2020-11-30
- **Final completion:** 2020-11-30
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2021-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04398004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04398004, "Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT04398004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*